Project Grant R15HL170243
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$409K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Kansas City, MO 64106, USA
Similar Awards
This $684,794 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund a research project to investigate the role of the blood vascular system and endothelial cells in the regeneration of the thymus after cytotoxic treatments. The research aims to utilize novel intravital imaging techniques to directly analyze changes in the thymus microenvironment, vascular heterogeneity, and tissue oxygenation in...
This $815,510 Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to develop a genetic-based classifier that can predict cancer patients' susceptibility to drug-induced cardiovascular toxicity. The University of Chicago, the prime awardee, will use a novel system of cardiac guided differentiation cultures and single-cell RNA sequencing to study the effects of three anticancer drugs...
This $2,060,460 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to develop a novel dual-targeting compound that prevents doxorubicin-induced cardiotoxicity (DICT) in cancer patients. The principal investigator at the University of Louisville will optimize the protective effects of this compound, determine its mechanisms of action in preventing DICT through cardiac CXCR7 activation...
This Project Grant award, issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $726,408 to the University of Cincinnati to define the role of endothelial TFEB in mitigating cardiovascular dysfunction induced by cancer therapy. The research aims to: 1) establish the effects of endothelial TFEB on chemotherapy-induced endothelial cell dysfunction and endothelial-cardiomyocyte interactions in vitro; 2) evaluate...
This $496,367 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to improve the efficacy of in situ reprogramming of cardiac fibroblasts into cardiomyocytes for treating myocardial infarction. The key products and services to be delivered include: Investigating the mechanism by which a repressor complex comprised of CBX1, PURB, and SP3 inhibits cardiomyocyte gene expression,...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $102,495 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University in St. Louis. The 2-year grant, effective August 1, 2024, will investigate how combined PD-1 inhibition and OX40 activation therapies reshape the cardiac immune landscape and promote myocardial vulnerability. The research aims to 1) understand the cardiac T-cell response, 2) elucidate the impact on monocyte...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, with a period of performance from January 2, 2025 to December 31, 2027, will support research to develop microphysiological systems that can precisely control oxygen levels to investigate the molecular pathways and functional effects of hypoxic injury on cardiomyocytes. The research aims to obtain a...
This $361,083 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research investigating how the acetylation of the transcriptional cofactor YAP regulates its subcellular localization and impacts cardiac regeneration. The research aims to understand how metabolic stresses influence YAP acetylation through the NAD+/SIRT1/2 axis, and whether combined targeting of the Hippo pathway and YAP...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to identify transcriptional regulators of endocardial-specific gene expression and understand how these regulate heart development, homeostasis, and regeneration. The award, totaling $540,856.00 and spanning from December 2024 to November 2028, will be conducted by the Regents of the University of California, San...